Diabetology and Endocrinology
Outline
Our department has a new structure as of January 2022. We are committed to promoting basic and clinical research to help diabetic patients lead a life equivalent to non-diabetic people. It is crucial to prevent complications. We will advocate for early therapeutic intervention to prevent cardiovascular complications and microvascular complications such as nephropathy. Moreover, we must aim to preserve and improve patients' quality of life through their diabetes care and treatment. As for research methods, continuing basic research using conventional mice and cells is essential, and we will actively conduct ethically-sound human studies to build evidence useful in daily clinical practice. In this process, we will apply various advanced clinical examination techniques and make full use of data analysis using digital devices and artificial intelligence in line with the current era. As a clinical department of a private medical university, we will continue to promote challenging and rewarding research for all department members.
e-mail: endocrin@kanazawa-med.ac.jp
Faculty
Professor and Chair
Professor (Adjunct)
Senior Assistant Professor
Senior Assistant Professor
Assistant Professor
YASUNAGA Yoko
Assistant Professor
IKOMA Maki
Assistant Professor
OZAWA Tsubasa
Adjunct Lecturer
KONISHI Kazunori
Adjunct Lecturer
SHIGIYAMA Fumika
Research Achievements
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with nonalcoholic fatty liver disease: A prospective randomized study.
Hiruma S, Shigiyama F, Kumashiro N.
Diabetes Obes Metab. 25(6):1576-1588, 2023.
Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis.
Daisuke Koya, Stefan D Anker, Luis M Ruilope, Peter Rossing, ZhiHong Liu, Byung Wan Lee, Chien-Te Lee, Charlie Scott,
Peter Kolkhof, Robert Lawatscheck, Lili Wang, Amer Joseph, Bertram Pitt; FIDELIO-DKD Investigators.
American Journal of Nephrology 54 (9-10):370-378, 2023.
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: a sub-analysis of the DIVERSITY-CVR study.
Kota Takuma, Ayako Fuchigami, Fumika Shigiyama, Naoki Kumashiro, Takahisa Hirose.
Diabetes, Obesity and metabolism 25(8):2131-2141, 2023.
Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
Shimada K, Kanasaki K, Kato M, Ogura Y, Takagaki Y, Monno I, Hirai T, Kitada M, Koya D.
J Diabetes Investig. 2022 Jun;13(6):955-964.
A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function,and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
Cardiovasc Diabetol. 2021 Feb 2;20(1):32.
External Research Funding
Manpei Suzuki Diabetes Foundation, Naoki Kumashiro, 2025
Grant-in-Aid for Scientific Research (C), Naoki Kumashiro, 2024-2026
Grant-in-Aid for Young Scientists, Fumika Shigiyama, 2022-2025